SEC Comment Letter 0000000000-24-003576 to PULSE BIOSCIENCES, INC. (PLSE)
PULSE BIOSCIENCES, INC.
Date: April 3, 2024 · CIK: 0001625101 · Accession: 0000000000-24-003576
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-278322
Letter
United States securities and exchange commission logo April 3, 2024 Kevin Danahy President and Chief Executive Officer Pulse Biosciences, Inc. 3957 Point Eden Way Hayward, California 94545 Re:Pulse Biosciences, Inc. Registration Statement on Form S-3 Filed March 28, 2024 File No. 333-278322 Dear Kevin Danahy: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Robert Augustin at 202-551-8483 with any questions. Sincerely, Division of Corporation Finance Office of Industrial Applications and Services cc: Adam Finerman
Show Raw Text
United States securities and exchange commission logo
April 3, 2024
Kevin Danahy
President and Chief Executive Officer
Pulse Biosciences, Inc.
3957 Point Eden Way
Hayward, California 94545
Re:Pulse Biosciences, Inc.
Registration Statement on Form S-3
Filed March 28, 2024
File No. 333-278322
Dear Kevin Danahy:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Robert Augustin at 202-551-8483 with any questions.
Sincerely,
Division of Corporation Finance
Office of Industrial Applications and
Services
cc: Adam Finerman